Glenmark Pharmaceuticals SA have declared top-line outcome from a Phase IIb dose range finding learning of Oglemilast in patients with COPD. The analyses showed that the once-daily cure with Oglemilast did not ensue in a statistically significant boost from baseline compared to panacea in the principal endpoint trough FEV1, a gauge of pulmonary function that is reduced in patients with COPD.
Besides, Oglemilast was well-endured at all measures analyzed. Oglemilast is a verbally managed phosphodiesterase 4 (PDE 4) inhibitor, which is supposed to be a significant and new therapeutic goal for COPD.
The medicine is still under the procedure of review for the cure of asthma, the outcome of which are likely in the early period of 2010.